ALLENDALE, N.J., March 24, 2015 /PRNewswire/ -- Stryker Corporation's Spine and Trauma & Extremities Divisions will be launching BIO4™, the next generation viable bone matrix at booth #443 during the American Academy of Orthopaedic Surgeons Annual Meeting in Las Vegas, NV from March 24-28th.
From the creators of the original allograft cellular bone matrix, Osiris Therapeutics, Inc., comes the next generation, BIO4, a viable bone matrix containing endogenous bone forming cells including mesenchymal stem cells, osteoprogenitor cells, osteoblasts, osteoinductive and angiogenic growth factors. BIO4 possesses all four characteristics involved in bone repair and regeneration: osteoconductive, osteoinductive, osteogenic and angiogenic.1, 2 It is a safe alternative to bone autograft that minimizes the potential for harvest site co-morbidities3.
"With the introduction of BIO4, Stryker now plays in the growing $199M4 Cellular Allograft Market," said Spencer Stiles, President, Stryker Spine. "Stryker offers one of the most comprehensive biologics portfolios on the market featuring the #1 selling synthetic bone graft5, Vitoss, and the next generation viable bone matrix, BIO4."
"BIO4 is a new therapeutic alternative to autograft for Foot and Ankle surgery, which avoids secondary surgical sites necessary to harvest autograft tissue," said Tom Popeck, Vice President and General Manager, Stryker Foot and Ankle. "Unlike many other alternatives to autograft, BIO4 possesses the four characteristics that are important for bone regeneration in a wide range of procedures. We are excited to enter into this new opportunity."
Stryker is one of the world's leading medical technology companies and together with our customers, we are driven to make healthcare better. The Company offers a diverse array of innovative medical technologies, including reconstructive, medical and surgical, and neurotechnology & spine products to help people lead more active and more satisfying lives. Stryker products and services are available in over 100 countries around the world. For more information, please visit our website at www.stryker.com.
About Osiris Therapeutics:
Osiris Therapeutics, Inc., based in Columbia, Maryland, is the world leader in researching, developing and marketing regenerative medicine products that improve health and lives of patients and lower overall healthcare costs. Having developed the world's first approved stem cell drug, the company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine – including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in orthopaedics, sports medicine and wound care, including BIO4, Cartiform® and Grafix®.
Osiris, Grafix, and Cartiform are registered trademarks of Osiris Therapeutics, Inc. BIO4 is a trademark of Stryker Corporation. More information can be found on the company's website, www.Osiris.com.
1 Osiris Report – Data on File
2 Roberts and Rosenbaum, "Bone grafts, bone substitutes and orthobiologics", Organogenesis (2012)
3 Not indicated for use with intervertebral body fusion devices
4 Millennium Research Group US Markets for Orthopedic Biomaterials 2013
5 Millennium Research Group: US Markets for Orthopedic Biomaterials 2014